Across TCGA pan-cancer cohorts, GJE1 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of GJE1’s most consistent transcriptional readouts.
The strongest signal is observed in stomach adenocarcinoma (STAD), where GJE1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GJE1 is over-expressed in tumor.
STAD are the cancer types where GJE1 tumor–normal differential expression is most reproducible.